ScreenerHero

PRME Prime Medicine, Inc.

NAS · US · Healthcare · Biotechnology · primemedicine.com
3.580USD-8.21%Mkt Cap: 649.33M $P/E: —

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap649.33M USD
Enterprise Value640.07M USD
Revenue (TTM)4.07M USD
Gross Profit-142.13M USD
Net Income (TTM)-201.14M USD
Revenue/Share0.02 USD
Last Price3.580 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees146
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.94
PEG—
EV/EBITDA-3.38
EV/Revenue157.15
P/S155.86
P/B15.56
EPS (TTM)-1.17
EPS (Forward)-0.89
52W Range
2.67021% of range6.940
52W High6.940 USD
52W Low2.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-3750.87%
EBITDA Margin0.00%
Profit Margin-4342.44%
ROE-166.41%
ROA-58.69%
Growth
Revenue Growth3.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.56M USD
CapEx (TTM)4.53M USD
FCF Margin-1860.55%
FCF Yield-11.67%
Net Debt17.41M USD
Net Debt/EBITDA-0.09
Balance Sheet
Debt/Equity0.96
Current Ratio3.06
Quick Ratio3.00
Book Value/Sh0.23 USD
Cash/Share0.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.114 USD
Upside (mean)+98.7%
Target Range4.250 USD – 11.00 USD
4.250+98.7% to mean11.00
# Analysts11
Ownership
Shares Out.181.38M
Float112.25M
Insiders20.30%
Institutions71.00%
Short Interest
Short Ratio11.7d
Short % Float22.65%
Short % Out.17.72%
Shares Short32.13M
Short (prev mo.)35.02M
Technical
SMA 503.228 (+10.9%)
SMA 2003.478 (+2.9%)
Beta2.38
S&P 52W Chg16.45%
Avg Vol (30d)3.92M
Avg Vol (10d)3.77M
Technical Indicators
RSI (14)56.8
MACD0.0446
MACD Signal-0.0225
MACD Hist.+0.0671
BB Upper3.780 USD
BB Middle3.239 USD
BB Lower2.697 USD
BB Width33.45%
ATR (14)0.3078 USD
Vol Ratio (20d)1.84x